Collecting data on pancreatic cancer treatment outcomes using NanoKnife
AHPBA Registry Database (Collection of Clinical Data Related to Pancreatic Cancer & Treatment - Irreversible Electroporation (IRE))
This study is collecting information on how well the NanoKnife treatment works for people with pancreatic cancer to help doctors improve their care.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 30 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Methodist Health System Academic / other |
| Locations | 1 site (Dallas, Texas) |
| Trial ID | NCT05170802 on ClinicalTrials.gov |
What this trial studies
This observational study aims to gather clinical data on the treatment outcomes of pancreatic cancer patients undergoing the NanoKnife procedure, an irreversible electroporation technique. It is an international, multi-center registry that will track patient progress and complications over a four-year period, with follow-ups at various intervals post-procedure. The data collected will help physicians improve care for patients requiring surgical intervention for pancreatic cancer. The study is overseen by the Americas Hepato-Pancreato-Biliary Association, which will ensure data quality and support institutions with suboptimal outcomes.
Who should consider this trial
Good fit: Ideal candidates are adults over 18 diagnosed with pancreatic cancer who are consenting to undergo the NanoKnife procedure.
Not a fit: Patients who do not meet the inclusion criteria or are not candidates for the NanoKnife procedure will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance treatment strategies and outcomes for patients with pancreatic cancer.
How similar studies have performed: While this approach is novel in the context of pancreatic cancer, similar studies using the NanoKnife system have shown promise in other applications.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. more than 18 years of age 2. Diagnosed with pancreatic cancer and has consented to undergo the NanoKnife procedure per the treating physician 3. Willing and able to comply with the protocol requirements 4. Able to comprehend and sign the Informed Consent Form in English or Spanish Exclusion Criteria: * Patients who meet any of the following criteria will be excluded from the study: 1. Do not meet the Study Inclusion Criteria laid out above
Where this trial is running
Dallas, Texas
- Liver Institute of Methodist Dallas Medical Center — Dallas, Texas, United States (Recruiting)
Study contacts
- Principal investigator: Alejandro Mejia, M.D. — The Methodist Hospital Research Institute
- Study coordinator: Crystee Cooper, DHEd
- Email: clinicalresearch@mhd.com
- Phone: 214-947-1280
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.